Maplelane Capital’s Sarepta Therapeutics SRPT Stock Holding History

Maplelane Capital’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-100,000	Closed	-$1.91M	–	157
2016 Q2	$1.91M	Buy	+100,000	New	+$1.85M	0.08%	93

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TCP

Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Maplelane Capital's SRPT Position: Q3 2016 in Review

Maplelane Capital sold out of Sarepta Therapeutics (SRPT) in Q3 2016, closing a stake of 1 share.

Maplelane Capital first reported a position in SRPT in Q2 2016 and held it in 1 quarter. The position peaked at $0 in Q2 2016. 186 funds tracked by Wall St. Rank hold SRPT as of Q3 2016.

Maplelane Capital reported no remaining Sarepta Therapeutics position as of Q3 2016 after selling out during the quarter.
Maplelane Capital sold 1 Sarepta Therapeutics share in Q3 2016.
Maplelane Capital first reported a position in Sarepta Therapeutics in Q2 2016 and held it in 1 quarter.
Maplelane Capital's Sarepta Therapeutics position peaked at $0 in Q2 2016.
186 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2016.

Based on Maplelane Capital's 13F filing for Q3 2016, filed 14 Nov 2016.